Actively Recruiting
Posterior Nasal Nerve Combined with Anterior Ethmoid Neurotomy for Idiopathic Rhinitis
Led by Xu Yu · Updated on 2025-03-11
150
Participants Needed
2
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The present study was a randomised, parallel controlled, open-label, multicentre clinical study. The trial was divided into two groups, the posterior nasal nerve combined with anterior ethmoid neurotomy group (group A) and the conventional drug treatment group (group B). Patients with idiopathic rhinitis (IR) who met the inclusion criteria were included in a 7-day introductory period of nasal spray hormone (Budesonide nasal spray) treatment. Subjects with IR who met the randomization criteria after the introductory period were randomized 1:1 to either group A or group B for a 1-year treatment follow-up study. In group A, subjects will undergo the posterior nasal nerve combined with anterior ethmoid neurotomy. In group B, subjects will be treated with medication according to guideline recommendations when nasal-related symptoms occur. Oral antihistamines (Loratadine) or nasal antihistamines (Azelastine Hydrochloride) are preferred, and nasal hormones (Budesonide nasal spray), or a combination of two or three drugs, may be used in severe cases. Participants will be evaluated for safety and efficacy throughout the entire three-year period.
CONDITIONS
Official Title
Posterior Nasal Nerve Combined with Anterior Ethmoid Neurotomy for Idiopathic Rhinitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and understood study explanation
- Age between 18 and 65 years with BMI between 19 and 24 kg/m2
- Diagnosed with idiopathic rhinitis with at least 2 nasal symptoms (obstruction, rhinorrhea, itching, sneezing) lasting over 1 year
- Negative skin prick test or specific IgE
- Nasal cytology showing eosinophils less than 20%
- Total Nasal Symptom Score (TNSS) of 6 or greater with nasal discharge subscore at least 2 and nasal congestion subscore at least 1
You will not qualify if you...
- Presence of colored nasal secretions, inflammation, nasal polyps, chronic sinusitis, or nasal tumors
- Other chronic rhinitis types such as occupational, drug-induced, gustatory, hormonal, or atrophic rhinitis
- Anatomical nasal abnormalities causing symptoms
- Nasal or sinus surgery within 3 months prior to enrollment
- Severe mental illness
- Uncontrolled asthma, systemic diseases, or cancer
- History of chronic smoking, substance abuse, drug use, or excessive alcohol consumption
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Renmin Hospital of Wuhan University
Wuhan, Hubei, China, 430060
Not Yet Recruiting
2
Renmin Hospital of Wuhan University
Wuhan, Hubei, China, 430060
Actively Recruiting
Research Team
Y
Yu Xu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here